Evaluation of treatment protocols based on the ESMO-magnitude of clinical benefit scale for gastrointestinal system cancers and their relationship with reimbursement policies in Turkey

IF 2 Q3 HEALTH POLICY & SERVICES

Journal of Cancer Policy Pub Date : 2025-05-05 DOI:10.1016/j.jcpo.2025.100590

Orhun Akdogan , Osman Sutcuoglu , Kadriye Bir Yucel , Ozan Yazici , Ahmet Ozet , Nuriye Ozdemir

{"title":"Evaluation of treatment protocols based on the ESMO-magnitude of clinical benefit scale for gastrointestinal system cancers and their relationship with reimbursement policies in Turkey","authors":"Orhun Akdogan , Osman Sutcuoglu , Kadriye Bir Yucel , Ozan Yazici , Ahmet Ozet , Nuriye Ozdemir","doi":"10.1016/j.jcpo.2025.100590","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Gastrointestinal system (GIS) cancers are a major global health challenge, with access to innovative therapies limited in resource-constrained settings. This study evaluates GIS cancer treatments in Turkey using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) and examines their reimbursement status.</div></div><div><h3>Methods</h3><div>Seventy-four treatment protocols were assessed using ESMO-MCBS, focusing on survival and quality-of-life benefits. Cost analyses of non-reimbursed protocols were conducted using the RxMedia Pharma 2024 database for a 70 kg patient.</div></div><div><h3>Results</h3><div>Only 31 % of the protocols were reimbursed, with nearly all curative regimens covered. In contrast, most metastatic treatments were non-reimbursed, despite significant clinical benefits. Non-reimbursed protocols with ESMO-MCBS scores ≥ 4 had 3-month costs ranging from $1000 to $10,000.</div></div><div><h3>Conclusion</h3><div>High-value therapies for GIS cancers remain largely inaccessible due to financial barriers. Incorporating ESMO-MCBS scores into reimbursement policies could improve access to effective treatments and align healthcare spending with clinical outcomes.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"44 ","pages":"Article 100590"},"PeriodicalIF":2.0000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Policy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213538325000347","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Gastrointestinal system (GIS) cancers are a major global health challenge, with access to innovative therapies limited in resource-constrained settings. This study evaluates GIS cancer treatments in Turkey using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) and examines their reimbursement status.

Methods

Seventy-four treatment protocols were assessed using ESMO-MCBS, focusing on survival and quality-of-life benefits. Cost analyses of non-reimbursed protocols were conducted using the RxMedia Pharma 2024 database for a 70 kg patient.

Results

Only 31 % of the protocols were reimbursed, with nearly all curative regimens covered. In contrast, most metastatic treatments were non-reimbursed, despite significant clinical benefits. Non-reimbursed protocols with ESMO-MCBS scores ≥ 4 had 3-month costs ranging from $1000 to $10,000.

Conclusion

High-value therapies for GIS cancers remain largely inaccessible due to financial barriers. Incorporating ESMO-MCBS scores into reimbursement policies could improve access to effective treatments and align healthcare spending with clinical outcomes.

查看原文本刊更多论文

基于esmo临床获益量表评估胃肠系统癌症治疗方案及其与土耳其报销政策的关系

胃肠道系统（GIS）癌症是一项重大的全球健康挑战，在资源受限的环境下，获得创新疗法的机会有限。本研究使用欧洲肿瘤医学学会临床获益等级量表（ESMO-MCBS）评估土耳其的GIS癌症治疗，并检查其报销状况。方法采用ESMO-MCBS对74种治疗方案进行评估，重点关注生存和生活质量方面的益处。使用RxMedia Pharma 2024数据库对70 kg的患者进行非报销方案的成本分析。结果只有31% %的方案得到了报销，几乎涵盖了所有的治疗方案。相比之下，尽管有显著的临床疗效，大多数转移性治疗都没有报销。ESMO-MCBS评分≥ 4的非报销方案的3个月费用从1000美元到10,000美元不等。结论由于经济上的障碍，GIS癌症的高价值治疗在很大程度上仍然难以获得。将ESMO-MCBS评分纳入报销政策可以改善获得有效治疗的机会，并使医疗支出与临床结果保持一致。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊